Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma - PubMed (original) (raw)
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma
Lars A Ormandy et al. Cancer Res. 2005.
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with a poor prognosis and one for which immunotherapy remains a viable option. Experimental tumor models have shown that regulatory T cells, a functionally unique subset of T cells, can suppress effective antitumor immune responses. This suppression might explain the poor outcome of some of the immunotherapy protocols currently being used. A better understanding of the role of regulatory T cells in HCC is important for design of future immunotherapy-based clinical protocols. We have studied regulatory T cells from 84 patients with HCC and 74 controls, including healthy donors, patients with chronic hepatitis B virus and hepatitis C virus infection and nonviral liver cirrhosis. Regulatory T cells were identified by fluorescence-activated cell sorting using a panel of antibodies and by real-time PCR analysis for Foxp3 expression. Functional studies were done to analyze their inhibitory role. Finally, regulatory T cells were analyzed in tumors and ascites from patients with HCC. Patients with HCC have increased numbers of CD4+CD25+ regulatory T cells in their peripheral blood, which express high levels of HLA-DR, GITR, and low or no CD45RA. These cells were anergic toward T-cell receptor stimulation and, when cocultured with activated CD4+CD25- cells, potently suppressed their proliferation and cytokine secretion. There were also high numbers of regulatory T cells in tumor-infiltrating lymphocytes of HCC patients comparable with the increase in their peripheral blood. Our data suggest that the increase in frequency of regulatory T cells might play a role in modulation of the immune response against HCC and could be important in design of immunotherapeutic approaches.
Similar articles
- Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS. Fu J, et al. Gastroenterology. 2007 Jun;132(7):2328-39. doi: 10.1053/j.gastro.2007.03.102. Epub 2007 Apr 14. Gastroenterology. 2007. PMID: 17570208 - Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.
Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ. Unitt E, et al. Hepatology. 2005 Apr;41(4):722-30. doi: 10.1002/hep.20644. Hepatology. 2005. PMID: 15791620 - Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
Yang ZQ, Yang ZY, Zhang LD, Ping-Bie, Wang SG, Ma KS, Li XW, Dong JH. Yang ZQ, et al. Hum Immunol. 2010 Dec;71(12):1180-6. doi: 10.1016/j.humimm.2010.09.011. Epub 2010 Sep 24. Hum Immunol. 2010. PMID: 20870003 - Immune responses in hepatocellular carcinoma.
Korangy F, Höchst B, Manns MP, Greten TF. Korangy F, et al. Dig Dis. 2010;28(1):150-4. doi: 10.1159/000282079. Epub 2010 May 7. Dig Dis. 2010. PMID: 20460904 Review. - Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
Geissler M, Mohr L, Ali MY, Grimm CF, Ritter M, Blum HE. Geissler M, et al. Z Gastroenterol. 2003 Nov;41(11):1101-10. doi: 10.1055/s-2003-44304. Z Gastroenterol. 2003. PMID: 14648380 Review.
Cited by
- Tumor Resection in Hepatic Carcinomas Restores Circulating T Regulatory Cells.
Martín-Sierra C, Martins R, Coucelo M, Abrantes AM, Caetano Oliveira R, Tralhão JG, Botelho MF, Furtado E, Domingues MR, Paiva A, Laranjeira P. Martín-Sierra C, et al. J Clin Med. 2024 Oct 9;13(19):6011. doi: 10.3390/jcm13196011. J Clin Med. 2024. PMID: 39408071 Free PMC article. - Fibrosis and Hepatocarcinogenesis: Role of Gene-Environment Interactions in Liver Disease Progression.
Banerjee A, Farci P. Banerjee A, et al. Int J Mol Sci. 2024 Aug 8;25(16):8641. doi: 10.3390/ijms25168641. Int J Mol Sci. 2024. PMID: 39201329 Free PMC article. Review. - Peptide-stimulated T cells bypass immune checkpoint inhibitor resistance and eliminate autologous microsatellite instable colorectal cancer cells.
Schwarz S, Su Z, Krohn M, Löffler MW, Schlosser A, Linnebacher M. Schwarz S, et al. NPJ Precis Oncol. 2024 Jul 29;8(1):163. doi: 10.1038/s41698-024-00645-3. NPJ Precis Oncol. 2024. PMID: 39075115 Free PMC article. - Exploring the Role of GITR/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma.
Papadakos SP, Chatzikalil E, Vakadaris G, Reppas L, Arvanitakis K, Koufakis T, Siakavellas SI, Manolakopoulos S, Germanidis G, Theocharis S. Papadakos SP, et al. Cancers (Basel). 2024 Jul 22;16(14):2609. doi: 10.3390/cancers16142609. Cancers (Basel). 2024. PMID: 39061246 Free PMC article. Review. - The Adaptive Immune Response in Hepatitis B Virus-Associated Hepatocellular Carcinoma Is Characterized by Dysfunctional and Exhausted HBV-Specific T Cells.
Broholm M, Mathiasen AS, Apol ÁD, Weis N. Broholm M, et al. Viruses. 2024 Apr 29;16(5):707. doi: 10.3390/v16050707. Viruses. 2024. PMID: 38793588 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials